Opinion

Video

Moving Beyond The Joint: Unraveling Gout's Systemic and Renal Implications

Key opinion leaders analyze EULAR 2024 updates on gout, chronic inflammation's systemic impact, and gout-chronic kidney disease (CKD) connections, while examining urate-lowering therapies for gout management, particularly in patients with CKD.

Related Videos
Marcelo Kugelmas, MD | Credit: South Denver Gastroenterology
John Tesser, MD, Adjunct Assistant Professor of Medicine, Midwestern University, and Arizona College of Osteopathic Medicine, and Lecturer, University of Arizona Health Sciences Center, and Arizona Arthritis & Rheumatology Associates
Brigit Vogel, MD: Exploring Geographical Disparities in PAD Care Across US| Image Credit: LinkedIn
Eric Lawitz, MD | Credit: UT Health San Antonio
| Image Credit: X
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Stephen Nicholls, MBBS, PhD | Credit: Monash University
Marianna Fontana, MD, PhD: Nex-Z Shows Promise in ATTR-CM Phase 1 Trial | Image Credit: Radcliffe Cardiology
Zerlasiran Achieves Durable Lp(a) Reductions at 60 Weeks, with Stephen J. Nicholls, MD, PhD | Image Credit: Monash University
Related Content
US FDA logo in black over a white background. | Credit: US Food and Drug Administration
November 23rd 2024

FDA Approves Acoramidis (Attruby) for ATTR-CM

Patrick Campbell
Medical Ethics Unpacked: Ethical Considerations for Euthanasia and Medically-Assisted Suicide
November 22nd 2024

Medical Ethics Unpacked: Ethical Considerations for Euthanasia & Medical Assistance in Dying

Steven Levine, MD Dominic Sisti, PhD
Protein and Glycine in Allergens: Negative Correlation with Allergy Prevalence
November 22nd 2024

Protein and Glycine in Allergens: Negative Correlation with Allergy Prevalence

Tim Smith
Medical Ethics Unpacked:
November 22nd 2024

Medical Ethics Unpacked: Ethical Foundations and Background of Euthanasia & Medically-Assisted Suicide

Steven Levine, MD Dominic Sisti, PhD
FDA Issues CRL to Avacincaptad Pegol sNDA for Geographic Atrophy | Image Credit: US Food and Drug Administration
November 22nd 2024

FDA Issues CRL to Avacincaptad Pegol sNDA for Geographic Atrophy

Connor Iapoce
Esi Lamousé-Smith, MD, PhD | Credit: Johnson & Johnson
November 22nd 2024

J&J Submits sBLA for Guselkumab (Tremfya) Subcutaneous Induction Regimen in UC

Abigail Brooks, MA
© 2024 MJH Life Sciences

All rights reserved.